AGIO
Income statement / Annual
Last year (2023), Agios Pharmaceuticals, Inc.'s total revenue was $26.82 M,
an increase of 88.36% from the previous year.
In 2023, Agios Pharmaceuticals, Inc.'s net income was -$352.09 M.
See Agios Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$26.82 M
|
$14.24 M
|
$0.00
|
$203.20 M
|
$117.91 M
|
$94.39 M
|
$43.01 M
|
$69.89 M
|
$59.12 M
|
$65.36 M
|
| Cost of Revenue |
$9.50 M |
$1.70 M |
$18.78 M |
$2.81 M |
$1.32 M |
$1.40 M |
$292.68 M |
$220.16 M |
$141.83 M |
$100.37 M |
| Gross Profit |
$17.32 M |
$12.54 M |
-$18.78 M |
$200.39 M |
$116.60 M |
$92.99 M |
-$249.67 M |
-$150.27 M |
-$82.71 M |
-$35.01 M |
| Gross Profit Ratio |
0.65 |
0.88 |
0 |
0.99 |
0.99 |
0.99 |
-5.8 |
-2.15 |
-1.4 |
-0.54 |
| Research and Development
Expenses |
$288.90 M
|
$279.91 M
|
$256.97 M
|
$367.47 M
|
$410.89 M
|
$341.32 M
|
$292.68 M
|
$220.16 M
|
$141.83 M
|
$100.37 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$71.12 M
|
$50.71 M
|
$35.99 M
|
$19.12 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$119.90 M
|
$121.67 M
|
$121.45 M
|
$149.07 M
|
$132.03 M
|
$114.15 M
|
$71.12 M
|
$50.71 M
|
$35.99 M
|
$19.12 M
|
| Other Expenses |
$0.00 |
$6.75 M |
$14.43 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$408.81 M |
$401.58 M |
$378.42 M |
$516.54 M |
$542.93 M |
$455.47 M |
$363.81 M |
$270.88 M |
$177.82 M |
$119.49 M |
| Cost And Expenses |
$418.31 M |
$403.29 M |
$378.42 M |
$519.35 M |
$544.25 M |
$456.87 M |
$363.81 M |
$270.88 M |
$177.82 M |
$119.49 M |
| Interest Income |
$33.34 M |
$12.79 M |
$836,000.00 |
$6.61 M |
$14.86 M |
$16.45 M |
$6.12 M |
$2.51 M |
$968,000.00 |
$203,000.00 |
| Interest Expense |
$0.00 |
$12.79 M |
$0.00 |
$17.83 M |
$0.00 |
$16.45 M |
$6.12 M |
$2.51 M |
$968,000.00 |
$203,000.00 |
| Depreciation &
Amortization |
$6.62 M
|
$18.56 M
|
$18.78 M
|
$18.77 M
|
$16.62 M
|
$7.17 M
|
$6.43 M
|
$5.71 M
|
$3.34 M
|
$1.37 M
|
| EBITDA |
-$384.86 M
|
-$380.48 M
|
-$337.73 M
|
-$326.13 M
|
-$394.85 M
|
-$338.86 M
|
-$314.36 M
|
-$195.28 M
|
-$115.36 M
|
-$52.77 M
|
| EBITDA Ratio |
-14.35 |
-36.99 |
0 |
-1.52 |
-3.55 |
-3.84 |
-7.46 |
-2.88 |
-2.01 |
-0.83 |
| Operating Income Ratio
|
-14.6
|
-27.32
|
0
|
-1.56
|
-3.62
|
-3.84
|
-7.46
|
-2.88
|
-2.01
|
-0.83
|
| Total Other
Income/Expenses Net |
$39.40 M
|
$157.25 M
|
$21.91 M
|
$6.61 M
|
$14.86 M
|
$16.45 M
|
$6.12 M
|
$2.51 M
|
$968,000.00
|
$203,000.00
|
| Income Before Tax |
-$352.09 M |
-$231.80 M |
-$356.51 M |
-$327.37 M |
-$411.47 M |
-$346.03 M |
-$314.67 M |
-$198.47 M |
-$117.73 M |
-$53.93 M |
| Income Before Tax Ratio
|
-13.13
|
-16.28
|
0
|
-1.61
|
-3.49
|
-3.67
|
-7.32
|
-2.84
|
-1.99
|
-0.83
|
| Income Tax Expense |
$0.00 |
-$157.25 M |
-$1.98 B |
$7.85 M |
-$14.86 M |
$32.90 M |
-$6.43 M |
-$5.71 M |
-$426,000.00 |
-$426,000.00 |
| Net Income |
-$352.09 M |
-$74.56 M |
$1.60 B |
-$335.22 M |
-$396.61 M |
-$346.03 M |
-$314.67 M |
-$198.47 M |
-$117.73 M |
-$53.50 M |
| Net Income Ratio |
-13.13 |
-5.24 |
0 |
-1.65 |
-3.36 |
-3.67 |
-7.32 |
-2.84 |
-1.99 |
-0.82 |
| EPS |
-6.33 |
-1.36 |
26.55 |
-4.86 |
-6.61 |
-6.03 |
-6.75 |
-5.07 |
-3.15 |
-1.59 |
| EPS Diluted |
-6.33 |
-1.36 |
26.55 |
-4.86 |
-6.61 |
-6.03 |
-6.75 |
-5.07 |
-3.15 |
-1.59 |
| Weighted Average Shares
Out |
$55.65 M
|
$54.79 M
|
$60.45 M
|
$69.00 M
|
$59.99 M
|
$57.42 M
|
$46.59 M
|
$39.13 M
|
$37.43 M
|
$33.67 M
|
| Weighted Average Shares
Out Diluted |
$55.65 M
|
$54.79 M
|
$60.45 M
|
$69.00 M
|
$59.99 M
|
$57.42 M
|
$46.59 M
|
$39.13 M
|
$37.43 M
|
$33.67 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
